Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds

Chemistry and Biology

Volumn 22, Issue 7, 2015, Pages 957-964

  Lang, Liwei ^a,d   Ding, Han Fei ^a   Chen, Xiaoguang ^b   Sun, Shi Yong ^c   Liu, Gang ^d   Yan, Chunhong ^a,d  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIS ACTING ELEMENT; INITIATION FACTOR 4E; MESSENGER RNA; RECOMBINASE; INTERNAL RIBOSOME ENTRY SITE;

ARTICLE; ASSAY; CANCER CELL CULTURE; CRISPR CAS SYSTEM; EPIGENETICS; FIBROSARCOMA; GENE CASSETTE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE LOCUS; GENE TECHNOLOGY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; REPORTER GENE; TRANSGENE; GENE; GENE TARGETING; GENETIC ENGINEERING; PROCEDURES; VALIDATION STUDY;

CRISPR-CAS SYSTEMS; GENE TARGETING; GENES; GENES, REPORTER; GENETIC ENGINEERING; HUMANS; INTERNAL RIBOSOME ENTRY SITES; TRANSCRIPTION, GENETIC;

EID: 84937726616     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2015.06.009     Document Type: Article

References (40)

1. D.S. Auld, N.T. Southall, A. Jadhav, R.L. Johnson, D.J. Diller, A. Simeonov, C.P. Austin, and J. Inglease Characterization of chemical libraries for luciferase inhibitory activity J. Med. Chem. 51 2008 2372 2386
2. J.B. Baell, and G.A. Holloway New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays J. Med. Chem. 53 2010 2719 2740
3. J. Baell, and M.A. Walters Chemical con artists foil drug discovery Nature 513 2014 481 483
4. A. Baer, and J. Bode Coping with kinetic and thermodynamic barriers: RMCE, an efficient strategy for the targeted integration of transgenes Curr. Opin. Biotech. 12 2001 473 480
5. P.B. Bitterman, and V.A. Polunovsky Attacking a nexus of the oncogenic circuitry by reversing aberrant eIF4F-mediated translation Mol. Cancer Ther. 11 2012 1051 1061
6. A.J. Bogdanove, and D.F. Voytas TAL effectors: customizable proteins for DNA targeting Science 333 2011 1843 1846
7. J.C. Burnett, J.J. Schmidt, R.G. Stafford, R.G. Panchal, T.L. Nguyen, A.R. Hermone, J.L. Vennerstorm, C.F. McGrath, D.J. Lane, E.A. Sausville, and et al. Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity Biochem. Biophys. Res. Commun. 310 2003 84 93
8. N.M. Chau, P. Rogers, W. Aherne, V. Carroll, I. Collins, E. McDonald, P. Workman, and M. Ashcroft Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors Cancer Res. 65 2005 4918 4928
9. K.C. Cheng, and J. Inglese A coincidence reporter-gene system for high-throughput screening Nat. Methods 9 2012 937
10. P. de Felipe, G.A. Luke, L.E. Hughes, D. Gani, C. Halpin, and M.D. Ryan E unum pluribus: multiple proteins from a self-processing polyprotein Trends Biotechnol. 24 2006 68 75
11. B.Y. Feng, A. Simeonov, A. Jadhav, K. Bagaoglu, J. Inglese, B.K. Shoichet, and C.P. Austin A high-throughput screen for aggregation-based inhibition in a large compound library J. Med. Chem. 50 2007 2385 2390
12. J. Graff, B. Konicek, T. Vincent, R. Lynch, D. Monteith, S. Weir, P. Schwier, A. Capen, R. Goode, M. Dowless, and et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity J. Clin. Invest. 117 2007 2638 2648
13. J. Graff, B. Konicek, J. Carter, and E. Marcusson Targeting the eukaryotic translation initiation factor 4E for cancer therapy Cancer Res. 68 2008 631 634
14. M. Gschwendt, H.J. Muller, K. Kielbassa, R. Zang, W. Kittstein, G. Rincke, and F. Marks Rottlerin, a novel protein kinase inhibitor Biochem. Biophys. Res. Commun. 199 1994 93 98
15. A.C. Hsieh, and D. Ruggero Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer Clin. Cancer Res. 16 2010 4914 4920
16. J. Inglese, P. Dranchak, J.J. Moran, S.-W. Jang, R. Srinivasan, Y. Santiago, L. Zhang, R. Guha, N. Martinez, R. MacArthur, and et al. Genome editing-enabled HTS assays expand drug target pathways for Charcot-Marie-Tooth disease AMC Chem. Biol. 9 2014 2594 2602
17. A.W. Kahsai, S. Zhu, D.J. Wardrop, W.S. Lane, and G. Fenteany Quinocarmycin analog DX-52-1 inhibits cell migration and targets radixin, disrupting interactions of radixin with actin and CD44 Chem. Biol. 13 2006 973 983
18. I.F. Khan, R.K. Hirata, and D.W. Russell AAV-mediated gene targeting methods for human cells Nat. Protoc. 6 2011 482 501
19. J.-S. Kim, C. Bonifant, F. BunZ, W.S. Lane, and T. Waldman Epitope tagging of endogenous genes in diverse human cell lines Nucleic Acid Res. 36 2008 e127
20. M. Levine, C. Cattoglio, and R. Tjian Looping back to leap forward: transcription enters a new era Cell 157 2014 13 25
21. G. Liao, X. Ma, and G. Liu An RNA-zipcode-independent mechanism that localizes Dia1 mRNA to the perinuclear ER through interactions between Dia1 nascent peptide and Rho-GTP J. Cell Sci. 124 2011 589 599
22. C.A. Lyssiotis, R.K. Foreman, J. Staerk, M. Garcia, D. Mathur, S. Markoulaki, J. Hanna, L.L. Lairson, B.D. Charette, L.C. Bouchez, and et al. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4 Proc. Natl. Acad. Sci. USA 106 2009 8912 8917
23. P. Mali, K.M. Esvelt, and G.M. Church Cas9 as a versatile tool for engineering biology Nat. Methods 10 2013 957 963
24. P. Martin, O. Albagli, M.C. Poggi, K.E. Boulukos, and P. Pognonec Development of a new bicistronic retroviral vector with strong IRES activity BMC Biotechnol. 6 2006 4
25. R. Nair, H. Avila, X. Ma, Z. Wang, M. Lennartz, B.G. Darnay, D.D. Boyd, and C. Yan A novel high-throughput screening system identifies a small molecule repressive for matrix metalloproteinase-9 expression Mol. Pharmacol. 73 2008 919 929
26. T. Nakahara, M. Takeuchi, I. Kinoyama, T. Minematsu, K. Shirasuna, A. Matsuhisa, A. Kita, F. Tominaga, K. Yamanaka, M. Kudoh, and M. Sasamata YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts Cancer Res. 67 2007 8014 8021
27. L.A. Pennacchio, W. Bickmore, A. Dean, M.A. Nobrega, and G. Bejerano Enhancers: five essential questions Nat. Rev. Genet. 14 2013 288 295
28. F.A. Ran, P.D. Hsu, J. Wright, V. Agarwala, D.A. Scott, and F. Zhang Genome engineering using the CRISPR-Cas9 system Nat. Protoc. 8 2013 2281 2308
29. A. Rapisarda, B. Uranchimeg, D.A. Scudiero, M. Selby, E.A. Sausville, R.H. Shoemaker, and G. Melillo Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway Cancer Res. 62 2002 4316 4324
30. A. Samsonov, N. Zenser, F. Zhang, H. Zhang, J. Fetter, and D. Malkov Tagging of genomic STAT3 and STAT1 with fluorescent proteins and insertion of a luciferase reporter in the cycline D1 gene provides a modified A549 cell line to screen for selective STAT3 inhibitors PLoS One 8 2013 e68391
31. T. Schlake, and J. Bode Use of mutated FLP recognition target (FRT) sites for the exchange of expression cassettes at defined chromosomal loci Biochemistry 33 1994 12746 12751
32. T.W. Schulte, and L.M. Neckers The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binding to HSP90 and shares important biologic activities with geldanamycin Cancer Chemother. Pharmacol. 42 1998 273 279
33. M. Stiborova, C.A. Bieler, M. Wiessler, and E. Frei The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts Biochem. Pharmacol. 62 2001 1675 1684
34. N. Thorne, J. Inglese, and D.S. Auld Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology Chem. Biol. 17 2010 646 657
35. F.D. Urnov, E.J. Rebar, M.C. Holmes, H.S. Zhang, and P.D. Gregory Genome editing with engineered zinc finger nucleases Nat. Rev. Genet. 11 2010 636 646
36. H. Wang, and C. Yan A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells Neoplasia 13 2011 611 619
37. H. Wang, X. Ma, S. Ren, J. Buolamwini, and C. Yan A small-molecule inhibitor of MDMX activates p53 and induces apoptosis Mol. Cancer Ther. 10 2011 69 79
38. C. Yan, and D.D. Boyd Histone H3 acetylation and H3 K4 methylation define distinct chromatin regions permissive for transgene expression Mol. Cell. Biol. 26 2006 6357 6371
39. C. Yan, and H.J. Paul Drugging the undruggable: transcription therapy for cancer Biochim. Biophys. Acta 1835 2013 76 85
40. C. Yan, H. Wang, B. Aggarwal, and D.D. Boyd A novel homologous recombination system to study 92 kDa type IV collagenase transcription demonstrates that the NF-κB motif drives the transition from a repressed to an activated state of gene expression FASEB J. 18 2004 540 541